Kintor Pharmaceutical Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	10.98	5	-	-	34.23	-
Revenue	10.98	5	-	-	34.23	-
Cost of Revenue	10.43	3.12	-4.13	-	-	-
Gross Profit	0.56	1.88	4.13	-	34.23	-
Selling, General & Admin	86.21	88.38	96.03	152.58	117.95	85.69
Research & Development	87.43	78.14	938.91	827.97	767.94	328.76
Other Operating Expenses	-18.48	-19.95	-7.49	-11.43	-16.96	-14.71
Operating Expenses	156.36	147.78	1,027	969.12	868.93	399.74
Operating Income	-155.8	-145.9	-1,023	-969.12	-834.7	-399.74
Interest Expense	-6.3	-9.28	-9.69	-8.19	-2.49	-3.38
Interest & Investment Income	0.81	4.21	13.08	6.88	12.05	10.42
Earnings From Equity Investments	-1.91	-1.43	0.05	-0.57	-	-
Currency Exchange Gain (Loss)	2.52	3.73	-3.13	16.33	-17.63	-118.29
EBT Excluding Unusual Items	-160.69	-148.67	-1,023	-954.67	-842.77	-511
Gain (Loss) on Sale of Investments	0	0	0.49	2	0.78	2.13
Gain (Loss) on Sale of Assets	-0.04	0	0.01	-0.62	-0.11	0.64
Asset Writedown	-6.62	-6.61	-46.36	-	-	-
Pretax Income	-167.34	-155.27	-1,069	-953.28	-842.1	-508.23
Income Tax Expense	-0.28	0.02	-8.04	1.09	-	0.07
Net Income	-167.07	-155.29	-1,061	-954.37	-842.1	-508.3
Net Income to Common	-167.07	-155.29	-1,061	-954.37	-842.1	-508.3
Shares Outstanding (Basic)	433	431	429	377	356	309
Shares Outstanding (Diluted)	433	431	429	377	356	309
Shares Change (YoY)	0.58%	0.39%	13.94%	5.66%	15.21%	29.24%
EPS (Basic)	-0.39	-0.36	-2.47	-2.53	-2.36	-1.64
EPS (Diluted)	-0.39	-0.36	-2.47	-2.53	-2.36	-1.64
Free Cash Flow	-159.9	-200.62	-390.3	-988.73	-1,128	-449.92
Free Cash Flow Per Share	-0.37	-0.47	-0.91	-2.63	-3.16	-1.45
Gross Margin	5.05%	37.58%	-	-	100.00%	-
Operating Margin	-1418.46%	-2918.00%	-	-	-2438.42%	-
Profit Margin	-1521.00%	-3105.84%	-	-	-2460.04%	-
Free Cash Flow Margin	-1455.79%	-4012.36%	-	-	-3294.09%	-
EBITDA	-137.01	-132.75	-1,009	-956.45	-827.97	-396.33
D&A For EBITDA	18.79	13.15	13.85	12.68	6.73	3.42
EBIT	-155.8	-145.9	-1,023	-969.12	-834.7	-399.74

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.